Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing

Borui Biopharmaceuticals (Suzhou) Co., Ltd. is a biopharmaceutical company that mainly engages in the R&D, production and sales of innovative drugs. The company's core products include: 1) Recombinant Human Coagulation Factor VIII for Injection; 2) Recombinant Human Coagulation Factor IX for Injection; 3) Human Serum Albumin for Injection; 4) Human Immunoglobulin Injection.


Borui Biopharmaceuticals (Suzhou) IPO Inquiry Response for STAR Market Listing - cover page
Brand
Borui Biopharmaceuticals (Suzhou)
Document type
Other
Language
Chinese
Pages
464
File format
PDF
File size
3.9 MB
Published
17 November, 2023
Updated
17 November, 2023
MD5 checksum
6B181B7DF033FD50F6E9E1B1CD7DD119

About this manual

This 464-page document contains Borui Biopharmaceuticals (Suzhou) Co., Ltd.'s detailed responses to the first round of inquiry letters from the Shanghai Stock Exchange concerning its IPO application on the Sci-Tech Innovation Board (STAR Market). Prepared with sponsor Minsheng Securities, the response addresses 49 questions across seven sections: equity structure and management basics, core technology, business operations, corporate governance and independence, financial accounting and management analysis, risk disclosures, and other matters. The excerpt shows detailed disclosure of new shareholders added in the prior year, including corporate shareholders Giant Sun and Guofa Qianhe, and partnership shareholders such as Sequoia Zhisheng, Hongpeng Investment, and Longmen Investment, with their equity structures and general partner information. This manual is written in Chinese.

What's inside

  • Equity structure and management basics
  • Core technology
  • Business operations
  • Corporate governance and independence
  • Financial accounting and management analysis
  • Risk disclosures
  • Other matters

Frequently asked questions

Who are the new corporate shareholders added in the year before the IPO inquiry response?

The new corporate shareholders are Giant Sun Investments HK Limited and Guofa Qianhe Investment Co., Ltd.

What is the equity structure of Giant Sun Investments HK Limited?

Giant Sun is 100% owned by HL Partners II L.P.

Which partnership enterprises became new shareholders?

The new partnership shareholders are Sequoia Zhisheng, Hongpeng Investment, Longmen Investment, Jingcheng Gaojin, and Zhuhai Zhangshi.

Download PDF (3.9 MB)